Options: Show MedDRA Preferred Terms
Side effect | Data for drug | Placebo | Labels | |||
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
Xerosis | 1% - 9% | x | x | x | ||
Tingling sensation | 1% - 29% | x | x | x | x | |
Pruritus | 0% - 11% | x | x | x | x | |
Dry skin | 1% - 9% | x | x | x | ||
Stinging | 1% - 16% | x | x | x | x | |
Erythema | 1% - 2% | x | x | |||
Dermatitis contact | 0% - 1% | x | x | x | x | |
Oedema | 0% - 1% | x | x | x | ||
Acne | 0% - 1% | x | x | x | ||
Iridocyclitis | postmarketing | x | x | x | ||
Asthma | x | x | x | x | ||
Dermatitis | x | |||||
Rash | x | |||||
Herpes labialis | x | x | x | x | ||
Hypersensitivity | x | |||||
Hypertrichosis | x | x | x | x | ||
Vitiligo | x | x | x | x | ||
Application site reaction | x | x | x | |||
Leukoderma | x | x | x | x | ||
Keratosis pilaris | x | x | x | x | ||
Redness | x | x | x | |||
Localized exfoliation | x | |||||
Phototoxicity | x | x | x |
Information about indications was extracted from the indications and usage sections of the labels.
standard – alternative
100% | ||
75% | ||
50% | ||
10% | ||
frequent (1% to 100%) | ||
infrequent (0.1% to 1%) | ||
rare (<0.1%) | ||
postmarketing | ||
0% | ||
no frequency information | ||
not found on label |